Avita Medical (ASX: AVH) received US Food and Drug Administration approval for its premarket approval supplement for the Recell Go mini, a disposable cartridge designed to treat smaller wounds up to 480 square centimeters, according to a Tuesday filing with the Australian bourse.
This extends the company's Recell Go platform, which previously handled larger wounds up to 1,920 square centimeters, the filing said.
The regenerative medicine company plans to roll out the product in the first quarter of 2025, targeting broader access to smaller wound care.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。